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Brief CommunicationsChanges in platelet aggregation after suspension of aspirin therapy
Kojiro Furukawa, MD, and Hitoshi Ohteki, MD, Saga, JapanAspirin medication is often suspended from 5 to 7 daysbefore cardiac surgery because of the risk of increasedperioperative blood loss.1 However, Dacey and col-leagues2 recently reported that preoperative aspirin
use among patients undergoing coronary artery bypass grafting
appears to be associated with a decreased risk of mortality, without
any significant increases in hemorrhage, blood product require-
ments, or related morbidities. Whether aspirin use or nonuse is the
more efficacious strategy remains a controversial question. Fur-
thermore, from the viewpoint of hard data, there are no clinical
reports about changes in platelet aggregation after stopping aspirin.
Patients and Methods
To standardize the platelet aggregation test, we used the grading
curve method.3 Four concentrations (0.25, 0.5, 1.0, and 2.0 g/
mL) of collagen (an aggregation inducer) were plotted along the
horizontal axis, and the corresponding percentages of aggregation
(5 minutes after collagen administration) were plotted along the
vertical axis. Rates of aggregation were measured with light trans-
mission by the method of Borns and Cross.4 We used the platelet
aggregator threshold index (PATI), which is obtained from the
grading curve, to represent the degree of platelet aggregation. The
PATI is the concentration of collagen that corresponds to 50% of
maximum aggregation3 (Figure 1). It correlates well with the
minimum concentration of irreversible aggregation, as the platelet
aggregation inducer.3 The grading curve and PATI were measured
automatically with a PAM 8T aggregometer (Mebanics Inc, To-
kyo, Japan). Twenty-two consecutively scheduled cardiac surgical
patients, each of whom received 81 mg of aspirin, were included
(13 male and 9 female patients, mean age 65  9.3 years, range
47-77 years). Fifteen were undergoing coronary artery bypass
grafting, and the remaining 7 were undergoing valve surgery.
PATIs were measured before and at 1, 2, 3, and 5 days after
stopping aspirin. All values were expressed as mean  SD. The
unpaired t test was performed for comparisons between the groups.
Results
The PATIs (in g/mL) before and 1, 2, 3, and 5 days after stopping
aspirin were 3.6  2.0, 1.7  1.2, 0.9  0.8, and 0.6  0.5,
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after stopping aspirin (P  .0007) and from 1 day to 3 days after
stopping (P  .01) (Figure 2).
Discussion
There are many evaluation methods for platelet aggregation, but
none of these has been defined as the standard. The evaluation of
platelet aggregation by a grading curve has been developed and
used in Japan. This method seems to enable easy determination of
the degree of aggregation and is considered to be useful for
monitoring platelet aggregation during the administration of anti-
platelet drugs.3 The PATI, which can be read from the grading
curve, correlates well with minimum concentrations of irreversible
aggregation.3 Therefore a low PATI indicates accelerated aggre-
gation, whereas a high one indicates reduced aggregation.
Aspirin inhibits the production of thromboxane A2 by irrevers-
ibly acetylating cyclooxygenase in the platelets. Thromboxane A2
Figure 1. Aggregation curve (left) and grading curve and defini-
tion of PATI (right). See text for details.
Figure 2. Overall results. (Asterisk indicates P < .05.)is essential to the normal clotting process initiated by the platelets.
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Brief CommunicationsThe loss of cyclooxygenase in platelets, which lack the capacity
for new protein synthesis, constitutes a loss of function for the
remainder of their lifetime. The average life span of platelets is 7
days; therefore the conventional practice is to stop aspirin therapy
1 week before the planned procedure. However, the results of this
study show that inhibition of platelet aggregation with aspirin
vanishes earlier than expected. The life span of the platelet and
platelet aggregation as a whole need to be understood separately.
Although it may take 10 days for the total platelet population to be
renewed and thus restore normal cyclooxygenase activity, it has
been shown in vitro that if as few as 20% of total platelets have
normal cyclooxygenase activity, aggregation would remain nor-
mal.5 Our study has confirmed this finding in the clinical situation.
This study has several limitations. One of these is the small
study population. We therefore should extend this study and in-
vestigate the outcomes. Another limitation concerns aspirin dos-
ages, which were low (81 mg/d) in this study. If the aspirin dosage
had been higher, the speed of recovery of aggregation might have
been different.
In conclusion, this study indicates that inhibition of plateletJean-Franc¸ois Bonneville, MD, and Joseph-Philippe Etievent, M
The Journal of Thoracication and vanished after 3 days. Therefore, in the presence of
preoperative aspirin therapy, stopping at 3 days before surgery
might be optimal for preventing bleeding complications. In addi-
tion, this study result should be considered when comparing aspi-
rin users versus nonusers in future investigations into the effects of
aspirin in cardiac surgery.
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Surgical pitfalls during explantation of a thoracic aortic
endoprosthesis
Lucian Stoica, MD, PhD,a Sidney Chocron, MD, PhD,a Pierre-Emmanuel Falcoz, MD,a
b aD, Besanc¸on, FranceWe report our experience with explantation of athoracic aortic endoprosthesis 2 years after theinitial procedure. This graft was explanted be-cause of failure of endovascular treatment of an
aneurysm that developed after surgical treatment of a type A aortic
dissection. Crossclamping of the aortic arch was impossible, and
surgery had to be performed with the patient under circulatory
arrest. The procedures performed are time-consuming under cir-
culatory arrest, making distal aortic arch surgery more complex
after endovascular repair than when performed at primary surgery.
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A 48-year-old man was operated on
for acute type-A aortic dissection.
We performed a supracoronary graft
replacement of the ascending aorta
under hypothermic circulatory arrest
with cerebral retroperfusion through
the superior vena cava.1 We found
only one intimal tear on the ascending aorta. The aortic valve was
spared. One year later, magnetic resonance imaging control re-
vealed a perfused false lumen with dilatation of the aorta to 53
mm. Aortography showed a communication between the two lu-
mens just below the origin of the left subclavian artery. A Talent
endoluminal stent graft (World Medical Corp, Sunrise, Fla) was
deployed 17 months after the first operation. It covered the origin of
the left subclavian artery, and the uncovered part was placed facing
the origin of the left common carotid artery. Because the false lumen
was still being perfused by the left subclavian artery, the origin of the
artery was completely obstructed with coils (Figure 1). The treatment
was completed with a bypass between the left carotid artery and the
left subclavian artery to avoid left arm ischemia.
Two years after endovascular treatment, the false lumen was
still perfused and the diameter of the postisthmic thoracic aorta had
increased to 57 mm (Figure 1). We performed the explantation of
Dr Stoicathe endoprosthesis through a left thor
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